ANNUAL RESULTS 2019/20
(End of fiscal year 30/09/20)

GROUP REVENUE

€4.7 Bn
An increase of 1.6% compared with 18/19 fiscal year (at real growth rate)

BREAKDOWN OF GROUP REVENUE
BY GEOGRAPHICAL AREA

- 28% EU (OUTSIDE FRANCE)
- 22% ASIA/OCEANIA
- 21% FRANCE
- 12% EUROPE (OUTSIDE EU)
- 11% AMERICAS
- 6% AFRICA/MIDDLE EAST

BREAKDOWN OF GROUP REVENUE
BY BUSINESS SEGMENT

- Cardio-metabolism 57%
- Oncology 10%
- Others (including central nervous system) 3%
- Generics 30%

TOP 5 CONTRIBUTING COUNTRIES
(brand-name medicines revenue)

U.S. €194 M
Russia €279 M
China €457 M
Italy €159 M
France €119 M

RESEARCH & DEVELOPMENT

- 23% of brand-name medicines revenue invested in R&D
- 50% of Servier R&D budget allocated to oncology as of fiscal year 2020/21

PRODUCTION IN FRANCE

- 32% of brand-name medicines are produced in France
- 98% of brand-name medicines active ingredients are manufactured in France

NUMBER OF BOXES DISTRIBUTED
(in millions)

- BOXES OF BRAND-NAME MEDICINES 643 M +2.9%
- BOXES OF GENERIC MEDICINES 539 M +5.3%